BioCentury
ARTICLE | Clinical News

Symbicort budesonide/formoterol: Phase III data

September 5, 2016 7:00 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Symbicort budesonide/formoterol Business: Inflammation Molecular target: Corticoid receptors; Adrenergic receptor beta 2 ( ADRB2) Descript...